Experts discuss the foundational role of topical therapies in pediatric atopic dermatitis management, highlighting the ...
Roflumilast 0.05% cream, a phosphodiesterase 4 inhibitor, was approved by the FDA on October 6, having been specifically ...
The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Up to 15 percent of children and five percent of adults are affected by the chronic inflammatory skin disease atopic dermatitis. Despite advanced therapy measures, the severe itching and eczema, ...
Incyte Biosciences Canada today announced that Health Canada has approved Opzelura® (ruxolitinib (as ruxolitinib phosphate)) ...
ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well ...
Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...
Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with rough, scaly patches. It affects up to 30% of children and 10% of adults, with about 60% of cases starting before age 1.
Credit: Getty Images. Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose. Recognizing the clinical diversity of ...
The FDA approved Zoryve cream 0.05% for the treatment of children aged 2 to 5 years with mild to moderate atopic dermatitis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback